These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26752166)

  • 1. An update on the strategies used for the treatment of chronic hepatitis B in children.
    Clemente MG; Vajro P
    Expert Rev Gastroenterol Hepatol; 2016; 10(5):649-58. PubMed ID: 26752166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updates in the management of hepatitis B in children.
    Lai MW; Chang MH
    Expert Rev Gastroenterol Hepatol; 2019 Nov; 13(11):1065-1076. PubMed ID: 31663387
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of patients with hepatitis B in special populations.
    Cholongitas E; Tziomalos K; Pipili C
    World J Gastroenterol; 2015 Feb; 21(6):1738-48. PubMed ID: 25684938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
    Viganò M; Mangia G; Lampertico P
    Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues.
    Dusheiko G
    Liver Int; 2013 Feb; 33 Suppl 1():137-50. PubMed ID: 23286858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues.
    Leung N
    Liver Int; 2011 Jan; 31 Suppl 1():85-9. PubMed ID: 21205143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A meta-analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection.
    Zuo SR; Zuo XC; Wang CJ; Ma YT; Zhang HY; Li ZJ; Song LY; Deng ZZ; Liu SK
    J Clin Pharmacol; 2015 Mar; 55(3):288-97. PubMed ID: 25293471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why do I treat HBeAg-positive chronic hepatitis B patients with a nucleoside analogue.
    Ma H; Jia J
    Liver Int; 2013 Feb; 33 Suppl 1():133-6. PubMed ID: 23286857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options.
    Jonas MM; Block JM; Haber BA; Karpen SJ; London WT; Murray KF; Narkewicz MR; Rosenthal P; Schwarz KB; McMahon BJ;
    Hepatology; 2010 Dec; 52(6):2192-205. PubMed ID: 20890947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations.
    Yuen MF; Ahn SH; Chen DS; Chen PJ; Dusheiko GM; Hou JL; Maddrey WC; Mizokami M; Seto WK; Zoulim F; Lai CL
    J Clin Gastroenterol; 2016 Apr; 50(4):286-94. PubMed ID: 26840752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update.
    Martin P; Lau DT; Nguyen MH; Janssen HL; Dieterich DT; Peters MG; Jacobson IM
    Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2071-87.e16. PubMed ID: 26188135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?
    Lampertico P; Viganò M; Colombo M
    Liver Int; 2013 Feb; 33 Suppl 1():157-63. PubMed ID: 23286860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent developments in antivirals against hepatitis B virus.
    Wang YJ; Yang L; Zuo JP
    Virus Res; 2016 Feb; 213():205-213. PubMed ID: 26732483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
    Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
    Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chronic hepatitis B: Evolution over two decades.
    Yuen MF; Lai CL
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
    Buster EH; Schalm SW; Janssen HL
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Latest developments in the treatment of hepatitis B.
    Dandri M; Petersen J
    Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?
    Kao JH
    Liver Int; 2014 Feb; 34 Suppl 1():112-9. PubMed ID: 24373087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.